Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 122, Issue 4, Pages 498-505
Publisher
Springer Science and Business Media LLC
Online
2019-12-20
DOI
10.1038/s41416-019-0683-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial
- (2017) Brigitte Dréno et al. LANCET ONCOLOGY
- Circulating Tumor Cells Expressing Markers of Tumor-Initiating Cells Predict Poor Survival and Cancer Recurrence in Patients with Pancreatic Ductal Adenocarcinoma
- (2016) Katherine E. Poruk et al. CLINICAL CANCER RESEARCH
- Genomic analyses identify molecular subtypes of pancreatic cancer
- (2016) Peter Bailey et al. NATURE
- Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer
- (2015) Daniel V.T. Catenacci et al. JOURNAL OF CLINICAL ONCOLOGY
- Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC
- (2015) Aleksandar Sekulic et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- The prognostic value of stroma in pancreatic cancer in patients receiving adjuvant therapy
- (2015) Katherine M. Bever et al. HPB
- Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival
- (2014) Berna C. Özdemir et al. CANCER CELL
- Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
- (2014) Andrew D. Rhim et al. CANCER CELL
- Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma
- (2014) E. J. Kim et al. CLINICAL CANCER RESEARCH
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
- (2012) J. Berlin et al. CLINICAL CANCER RESEARCH
- Sonic Hedgehog Signaling Inhibition Provides Opportunities for Targeted Therapy by Sulforaphane in Regulating Pancreatic Cancer Stem Cell Self-Renewal
- (2012) Mariana Rodova et al. PLoS One
- Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors
- (2011) P. M. LoRusso et al. CLINICAL CANCER RESEARCH
- Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
- (2011) Daniel D. Von Hoff et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combination of Hedgehog Signaling Blockage and Chemotherapy Leads to Tumor Reduction in Pancreatic Adenocarcinomas
- (2011) Marcus Bahra et al. PANCREAS
- Targeting Hedgehog -- a Cancer Stem Cell Pathway
- (2010) A. A. Merchant et al. CLINICAL CANCER RESEARCH
- Prognostic Significance of Tumorigenic Cells With Mesenchymal Features in Pancreatic Adenocarcinoma
- (2010) Zeshaan A. Rasheed et al. JNCI-Journal of the National Cancer Institute
- Sonic Hedgehog Expression Correlates With Distant Metastasis in Pancreatic Adenocarcinoma
- (2010) Juntao Dai et al. PANCREAS
- Blockade of hedgehog signaling pathway as a therapeutic strategy for pancreatic cancer
- (2009) Fu-Guo Xu et al. CANCER LETTERS
- A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development
- (2009) A. Jimeno et al. MOLECULAR CANCER THERAPEUTICS
- The Hedgehog Pathway and Pancreatic Cancer
- (2009) Manuel Hidalgo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
- (2009) K. P. Olive et al. SCIENCE
- Sonic Hedgehog Promotes Desmoplasia in Pancreatic Cancer
- (2008) J. M. Bailey et al. CLINICAL CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer
- (2008) G Feldmann et al. GUT
- An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer
- (2008) G. Feldmann et al. MOLECULAR CANCER THERAPEUTICS
- A paracrine requirement for hedgehog signalling in cancer
- (2008) Robert L. Yauch et al. NATURE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started